NCT03165422已完成不适用
A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 68 人开始时间: 2017年3月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 68
- 试验地点
- 1
- 主要终点
- Incidence of ipilimumab treatment after nivolumab treatment
研究概览
简要总结
This is a medical chart review of ipilimumab treatment after nivolumab treatment in melanoma in Japan
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients > 18 years of age or older
- •Diagnosis of advanced melanoma (unresectable/metastatic), alive or deceased as of date of data collection
- •Treated with ipilimumab between 31-Aug-2015 and 31-Mar-2017 before or after nivolumab treatment
排除标准
- •Patients enrolled in any clinical trials at any time
- •Overlapping use of nivolumab and ipilimumab
结局指标
主要结局
Incidence of ipilimumab treatment after nivolumab treatment
时间窗: Approximately 19 months
Incidence of nivolumab treatment after ipilimumab treatment
时间窗: Approximately 19 months
Duration of nivolumab treatment
时间窗: Approximately 19 months
Duration of ipilimumab treatment
时间窗: Approximately 19 months
Duration of interval between nivolumab treatment and ipilimumab treatment
时间窗: Approximately 19 months
次要结局
- overall response rate (ORR)(Approximately 19 months)
- best overall response rate (BORR)(Approximately 19 months)
- overall survival (OS)(Approximately 19 months)
- progression-free survival (PFS)(Approximately 19 months)
- incidence of treatment-related adverse events (AEs)(Approximately 19 months)
- severity of treatment-related adverse events (AEs)(Approximately 19 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in JapaMelanomaJPRN-UMIN000028628Bristol-Myers Squibb82
已完成
不适用
RETROSPECTIVE JAPANESE REAL WORLD STUDY OF METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB PLUS IPILIMUMAB (J-cardinal study)metastatic renal cell carcinoma (mRCC)JPRN-UMIN000035974Ono Pharmaceutical CO.,LTD. Bristol-Myers Squibb K.K.45
已完成
2 期
Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma PatientsMelanomaNCT01990859Bristol-Myers Squibb20
未知
2 期
Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma PatientsMelanomaJPRN-jRCT2080222335Bristol-Myers K.K.18
进行中（未招募）
4 期
A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.Malignant MelanomaNCT02068196Oslo University Hospital150